Drug
Becatecarin clinical trials
Also written XL119, BMS-181176 and DEAE-rebeccamycin.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 1999
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
12 studies that test it; most in 2000 (6)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2000 | 6 |
| 2004 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 11
National Cancer Institute (NCI) (6) · Case Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (1) · Barbara Ann Karmanos Cancer Institute (1) · Northwestern University (1) · Helsinn Healthcare SA (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses becatecarin is read from its arms, and is right about nine times in ten.
Testing it · 12
- Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line ChemotherapyTerminatedPhase 2National Cancer Institute (NCI)NCT00084487Written as becatecarin
- Rebeccamycin Analog in Treating Children With Relapsed or Refractory NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00003737Written as becatecarin
- Rebeccamycin Analog in Treating Patients With Advanced Kidney CancerCompletedPhase 2Barbara Ann Karmanos Cancer InstituteNCT00005027Written as becatecarin
- Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00005085Written as becatecarin
- Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT00006102Written as becatecarin
- Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00005817Written as becatecarin
- Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedPhase 1National Cancer Institute (NCI)NCT00087204Written as becatecarin
- Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid TumorsTerminatedPhase 1National Cancer Institute (NCI)NCT00086983Written as becatecarin
- Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial CancerTerminatedPhase 2Northwestern UniversityNCT00006262Written as becatecarin
- Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary CancerTerminatedPhase 2Case Comprehensive Cancer CenterNCT00005997Written as becatecarin
- Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedPhase 2Case Comprehensive Cancer CenterNCT00006017Written as becatecarin
- XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary TumorsTerminatedPhase 3Helsinn Healthcare SANCT00090025Written as becatecarin
Given in every arm · 1 — becatecarin is usual care beside what is tested
Codes
What other systems call becatecarin · ClinicalTrials.gg INT003839
- MeSH (NLM) C093269becatecarinOne source NLM
- UNII (FDA) A60X6MBU6GBECATECARINConfirmed FDA, NLM, Wikidata
- Wikidata Q27273671becatecarinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1620BecatecarinOne source FDA
- DrugBank DB06362One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C093269 | becatecarin | One source NLM |
| UNII (FDA) | A60X6MBU6G | BECATECARIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27273671 | becatecarin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1620 | Becatecarin | One source FDA |
| DrugBank | DB06362 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.